Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial MeningiomaSylvia C. Kurz, Erik P. Sulman, Elçin Zan et al.|Clinical Cancer Research|2023Cited by 55
CTNI-57. RADIONUCLIDE THERAPY WITH 177LU-DOTATATE (LUTATHERA) IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMA - INTERIM ANALYSIS RESULTS OF A SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE II STUDYSylvia C. Kurz, Erik P. Sulman, Elçin Zan et al.|Neuro-Oncology|2022Cited by 2
Data from Evaluation of the SSTR2-targeted Radiopharmaceutical <sup>177</sup>Lu-DOTATATE and SSTR2-specific <sup>68</sup>Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial MeningiomaSylvia C. Kurz, Erik P. Sulman, Elçin Zan et al.|Unknown|2024Cited by 1
CTNI-41. RESULTS OF A SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE 2 STUDY OF THE RADIOPHARMACEUTICAL [177LU]LU-DOTA-TATE IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMASylvia C. Kurz, Erik P. Sulman, Elçin Zan et al.|Neuro-Oncology|2025Cited by 1
TIP-15. Trial in progress: phase IB study of concurrent Azeliragon, a RAGE inhibitor, with craniospinal irradiation in patients with leptomeningeal metastasesK.M. Banson, Jonathan T. Yang, Judith D. Goldberg et al.|Neuro-Oncology|2025Cited by 0